{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.91 vs. cons $2.86",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$25.31B vs. cons $25.03B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "MedTech revenue",
      "prediction": "BEAT",
      "answer": "pred ~$9.03B vs. cons $8.90B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 reported sales guidance",
      "prediction": "BETTER",
      "answer": "guide ~$101.20B vs. cons $101.00B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$11.65 vs. cons $11.62 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 adjusted pretax operating-margin expansion",
      "prediction": "BETTER",
      "answer": "guide ~60 bps vs. cons 50 bps (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.4,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A ~$0.03 FY2026 EPS-guide increase versus $11.62 consensus, alongside ~$0.20B higher sales guidance versus $101.00B consensus, supports out-period estimate revisions rather than a one-day headline beat; MedTech acceleration and launch traction should reinforce the revision case.",
  "day5_confidence": "MEDIUM"
}